Search Results

There are 53856 results for: content related to: Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?

  1. Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 5, November 2008, Pages: 589–594, KP Kanebratt, U Diczfalusy, T Bäckström, E Sparve, E Bredberg, Y Böttiger, TB Andersson and L Bertilsson

    Article first published online : 23 JUL 2008, DOI: 10.1038/clpt.2008.132

  2. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone

    Clinical Pharmacology & Therapeutics

    Volume 68, Issue 4, October 2000, Pages: 356–366, Jeannine S. McCune, Roy L. Hawke, Edward L. LeCluyse, Heidi H. Gillenwater, Geraldine Hamilton, James Ritchie and Celeste Lindley

    Article first published online : 29 OCT 2000, DOI: 10.1067/mcp.2000.110215

  3. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5

    Clinical Pharmacology & Therapeutics

    Volume 78, Issue 6, December 2005, Pages: 605–618, Stéphane J. Mouly, Chris Matheny, Mary F. Paine, Glenn Smith, Jatinder Lamba, Vishal Lamba, Susan N. Pusek, Erin G. Schuetz, Paul W. Stewart and Paul B. Watkins

    Article first published online : 7 DEC 2005, DOI: 10.1016/j.clpt.2005.08.014

  4. You have free access to this content
    Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients

    British Journal of Clinical Pharmacology

    Volume 62, Issue 2, August 2006, Pages: 200–209, Stéphane Mouly, Nathalie Rizzo-Padoin, Guy Simoneau, Céline Verstuyft, Guy Aymard, Cécile Salvat, Isabelle Mahé and Jean-François Bergmann

    Article first published online : 2 MAY 2006, DOI: 10.1111/j.1365-2125.2006.02637.x

  5. Influence of a Nigerian honey on CYP3A4 biotransformation of quinine in healthy volunteers

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 5, October 2015, Pages: 545–549, S. I. Igbinoba, M. A. Akanmu, C. O. Onyeji, J. O. Soyinka, A. R. Owolabi, T. I. Nathaniel, S. V. Pullela and J. M. Cook

    Article first published online : 14 JUL 2015, DOI: 10.1111/jcpt.12303

  6. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans

    Clinical Pharmacology & Therapeutics

    Volume 70, Issue 6, December 2001, Pages: 505–517, Somphane Phimmasone and Evan D. Kharasch

    Article first published online : 16 DEC 2001, DOI: 10.1016/S0009-9236(01)23711-4

  7. You have free access to this content
    Gefitinib–phenytoin interaction is not correlated with the 14C-erythromycin breath test in healthy male volunteers

    British Journal of Clinical Pharmacology

    Volume 68, Issue 2, August 2009, Pages: 226–237, Stephanie Chhun, Celine Verstuyft, 1 Nathalie Rizzo-Padoin, 2 Guy Simoneau, Laurent Becquemont, 1 Ilana Peretti, 2 Alan Swaisland, 3 Robert Wortelboer, 4 Jean Francois Bergmann and Stephane Mouly

    Article first published online : 5 MAY 2009, DOI: 10.1111/j.1365-2125.2009.03438.x

  8. Effect of High-Dose Vitamin C on Hepatic Cytochrome P450 3A4 Activity

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 25, Issue 12, December 2005, Pages: 1725–1728, Dr. Rolf P. G. van Heeswijk, Dr. Curtis L. Cooper, Dr. Brian C. Foster, Mr. Bobby M. Chauhan, Dr. Farshad Shirazi, Dr. Isabelle Seguin, Dr. Elizabeth J. Phillips and Mr. Ed Mills

    Article first published online : 16 JAN 2012, DOI: 10.1592/phco.2005.25.12.1725

  9. Variability in Activity of Hepatic CYP3A4 in Patients Infected with HIV

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 20, Issue 8, August 2000, Pages: 898–907, Dr. Douglas Slain, Dr. Amy Pakyz, Dr. Debra S. Israel, Dr. Sara Monroe and Dr. Ron E. Polk

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.20.11.898.35262

  10. Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells

    Cell Biology International

    Volume 37, Issue 2, February 2013, Pages: 109–120, Ewa Augustin, Monika Pawłowska, Joanna Polewska, Agnieszka Potega and Zofia Mazerska

    Article first published online : 14 JAN 2013, DOI: 10.1002/cbin.10018

  11. Effects of Ritonavir-Boosted Lopinavir on the Pharmacokinetics of Quinine

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 5, May 2012, Pages: 889–895, M M Nyunt, Y Lu, Q Yu, M El-Gasim, T L Parsons, B G Petty and C W Hendrix

    Article first published online : 4 APR 2012, DOI: 10.1038/clpt.2011.326

  12. In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 3, September 2012, Pages: 366–375, H de Jonge, H de Loor, K Verbeke, Y Vanrenterghem and D R Kuypers

    Article first published online : 8 AUG 2012, DOI: 10.1038/clpt.2012.109

  13. Effect of Influenza Immunization on CYP3A4 Activity In Vivo

    The Journal of Clinical Pharmacology

    Volume 43, Issue 12, December 2003, Pages: 1377–1381, Dr. Mary S. Hayney and Dr. Daniel Muller

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270003260330

  14. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit

    British Journal of Clinical Pharmacology

    Volume 80, Issue 3, September 2015, Pages: 548–559, Hylke de Jonge, Thomas Vanhove, Henriëtte de Loor, Kristin Verbeke and Dirk R. J. Kuypers

    Article first published online : 3 AUG 2015, DOI: 10.1111/bcp.12703

  15. Poster Sessions

    Pharmacology & Toxicology

    Volume 89, Issue S1, December 2001, Pages: 37–147,

    Article first published online : 22 JAN 2015, DOI: 10.1111/j.0901-9928.2001.tb00002.x

  16. You have free access to this content
    Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates

    British Journal of Pharmacology

    Volume 165, Issue 8, April 2012, Pages: 2787–2798, AM Filppula, J Laitila, PJ Neuvonen and JT Backman

    Article first published online : 23 MAR 2012, DOI: 10.1111/j.1476-5381.2011.01732.x

  17. The roles of cytochrome P450 3A4 and lA2 in the 3-hydroxylation of quinine in vivo

    Clinical Pharmacology & Therapeutics

    Volume 66, Issue 5, November 1999, Pages: 454–460, Rajaa A. Mirghani, Urban Hellgren, Per Anton Westerberg, Orjan Ericsson, Leif Bertilsson and Lars L. Gustafsson

    Article first published online : 25 NOV 1999, DOI: 10.1016/S0009-9236(99)70008-1

  18. Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital

    The Journal of Clinical Pharmacology

    Volume 44, Issue 11, November 2004, Pages: 1273–1281, Niresh Hariparsad, Srikanth C. Nallani, Rucha S. Sane, Donna J. Buckley, Arthur R. Buckley and Pankaj B. Desai

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270004269142

  19. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

    Clinical Pharmacology & Therapeutics

    Volume 62, Issue 3, September 1997, Pages: 248–260, Kenneth S. Lown, Robert R. Mayo, Alan B. Leichtman, Hsiu-ling Hsiao, D. Kim Turgeon, Phyllissa Schmiedlin-Ren, Morton B. Brown, Wensheng Guo, Stephen J. Rossi, Leslie Z. Benet and Paul B. Watkins

    Article first published online : 22 SEP 1997, DOI: 10.1016/S0009-9236(97)90027-8

  20. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

    Clinical Pharmacology & Therapeutics

    Volume 71, Issue 3, March 2002, Pages: 196–204, Elena García-Martín, Carmen Martínez, Rosa M. Pizarro, Francisco J. García-Gamito, Harriet Gullsten, Hannu Raunio and José A. G. Agúndez

    Article first published online : 22 MAR 2002, DOI: 10.1067/mcp.2002.121371